Clinical Research Directory
Browse clinical research sites, groups, and studies.
Etoricoxib in Patients With Parkinsonian Disease
Sponsor: Ihab Elsayed Hassan
Summary
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
Official title: Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment
Key Details
Gender
All
Age Range
50 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-01-30
Completion Date
2027-11-20
Last Updated
2026-04-08
Healthy Volunteers
No
Conditions
Interventions
L-dopa
Levodopa is the standard therapy in PD.
Etoricoxib
Etoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia.
Locations (1)
Mansoura University
Al Mansurah, Egypt